Member Info for BuenaVista

Rubbish! The key opinion leaders in oncology will be there to detail timescales to market and when the next products will be coming along plus any licensing deals in the bag ... according to Toukmoron.

Try a bit of rape and pillage instead over the next couple of weeks then.

Toukmoron, you're a useless deramper. Just give it a rest and sit back and enjoy the ride everyone else is having ...which reminds me: that Kenny is one lucky guy ;0)

From my reading around the topic, FAPa seems to be involved in tiissue growth and regrowth/repair/scarring and is described as being upregulated compared to healthy tissues and sometimes explicitly healthy ADULT tissues.

e.g. https://www.google.com/search?q=fibroblast+fap+healthy+adult+tissues

Can someone with knowledge of the science shine a light on the age/stage of growth when children stop significant upregulation of FAPa? The obvious assumption is when growth stops around 17 or 18 but that's only an assumption - if growth starts to slow, so may FAPa upregulation (i.e. there's no sudden halt to the upregulation).

The mounted panto act is correct.

The conversion factor is 54/80.

This is because, going back to August 2021, Alan said the initial dose of AVA6000 of 80mg/m² was equivalent to 90% of the standard doxorubicin dose, which we took to be 60mg/m². This also matches up by calculating the molecular weights of the two.

So... 12 x 54 / 80 = 8.1 mg/m² of cequivalent
So... 12 mg AVA6000 : 2 mg doxorubicin is 8.1 : 2
Or 4.05 times the doxorubicin dosing

So the thread is about what data might be given to the investment community for Science Day and Prof Toukmoron is still bellyaching that Alan hasn't divulged all Avacta's trade secrets to the whole world? Brilliant!

Thanks SB

Btw, that was the new generic name for AVA6000.

efingfenomanol ?

A couple of questions:

Is a large print after hours a summary of trades already listed during the day or have the trades that made them not been reported?

Can a MM hold enough shares (obviously acquired at a lower price) to satisfy a large buy order and all the buy trades carried out during yesterday?

Surely that will mean 20x the US$3bn dox market then? Multiply by the standard industry 8.9x and that's $534bn just for dox. Add in the other 12 in the pipeline at half that amount and it's $3,738bn. Add a few $bn more for the rest of the IP and Avacta has to be worth at least $3,996bn, or £200 per share ex-Chi-nah. Does that sound right?

Onto a bit of a winner this lunchtime. Met a young lady in a pub. Well, young and lady are stretching it a bit but she's quite a goer and says her old man's gone to watch the G'ers and will be out getting blasted later, probably 8 to 10 pints and finishing with a stinky curry, so won't be back till late. Can't believe myluck. Will let you know how it goes.

Is he talking at Science Day as well?

And buy more at this bargain price!

If you're not selling - and nothing has changed - then it doesn't matter.

As Wyntwunt says, nothing here affects the share price.

Gotta say I was very impressed with C?llr. Stephen Cowan (Lab), Leader of Hammersmith & Fulham Council. We need more politicans with this person's vision and enthusiasm.

This exemplifies the size of the problem.

The FTSE techMARK 100 has only 19 constituent companies because there are only 19 in the FTSE techMARK All-Share Index. Tiny, but not necessarily the tiniest (I haven't looked), is Triad Group with a MCap of £19.07 million. How sad is that?

"Quite"? I suppose you're using the American version of the word.

Ignoranus

A cancer deathspiral?